Now showing items 1-5 of 5

    • An oncogenic Ezh2 mutation cooperates with particular genetic alterations to induce tumors in mice and redistributes H3K27 trimethylation throughout the genome 

      Souroullas, George P.; Jeck, William R.; Parker, Joel S.; Simon, Jeremy M.; Liu, Jie-Yu; Paulk, Joshiawa; Xiong, Jessie; Clark, Kelly S.; Fedoriw, Yuri; Qi, Jun; Burd, Christin E.; Bradner, James E.; Sharpless, Norman E. (2016)
      B-cell lymphoma and melanoma harbor recurrent mutations in the gene encoding the EZH2 histone methyltransferase, but the carcinogenic role of these mutations is unclear. Here we describe a mouse model in which the most ...
    • Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia 

      Reynolds, Christine; Roderick, Justine E.; LaBelle, James L.; Bird, Gregory; Mathieu, Ronald; Bodaar, Kimberly; Colon, Diana; Pyati, Ujwal; Stevenson, Kristen E.; Qi, Jun; Harris, Marian; Silverman, Lewis B.; Sallan, Stephen E.; Bradner, James E.; Neuberg, Donna S.; Look, A. Thomas; Walensky, Loren D.; Kelliher, Michelle A.; Gutierrez, Alejandro (2014)
      Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with PTEN deletions and resultant PI3K-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial ...
    • Response and resistance to BET bromodomain inhibitors in triple negative breast cancer 

      Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Tabassum, Doris P.; Roberts, Justin M.; Janiszewska, Michalina; Huh, Sung Jin; Liang, Yi; Ryan, Jeremy; Doherty, Ernest; Mohammed, Hisham; Guo, Hao; Stover, Daniel G.; Ekram, Muhammad B.; Brown, Jonathan; D'Santos, Clive; Krop, Ian E.; Dillon, Deborah; McKeown, Michael; Ott, Christopher; Qi, Jun; Ni, Min; Rao, Prakash K.; Duarte, Melissa; Wu, Shwu-Yuan; Chiang, Cheng-Ming; Anders, Lars; Young, Richard A.; Winer, Eric; Letai, Antony; Barry, William T.; Carroll, Jason S.; Long, Henry; Brown, Myles; Liu, X. Shirley; Meyer, Clifford A.; Bradner, James E.; Polyak, Kornelia (2015)
      Triple negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy1-3. BET bromodomain inhibitors, which have shown efficacy in several models of cancer4-6, ...
    • Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2 

      Liu, Suhu; Walker, Sarah Rebecca; Nelson, E; Cerulli, R.; Xiang, Michael; Toniolo, P. A.; Qi, Jun; Stone, Richard Maury; Wadleigh, Martha; Bradner, James Elliott; Frank, David Alan (American Association for Cancer Research (AACR), 2014)
      The transcription factor signal STAT5 is constitutively activated in a wide range of leukemias and lymphomas, and drives the expression of genes necessary for proliferation, survival, and self-renewal. Thus, targeting STAT5 ...
    • Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6 

      Hu, Yu-Jie; Belaghzal, Houda; Hsiao, Wen-Yu; Qi, Jun; Bradner, James E.; Guertin, David A.; Sif, Saïd; Imbalzano, Anthony N. (Oxford University Press, 2015)
      Jumonji domain-containing protein 6 (JMJD6) is a nuclear protein involved in histone modification, transcription and RNA processing. Although JMJD6 is crucial for tissue development, the link between its molecular functions ...